“Peptides” have become one of the most talked-about subjects in weight loss. The term appears everywhere: on social media, in conversations about GLP-1 medications and increasingly alongside claims about new treatments promising dramatic results. But what exactly is a peptide, and what does it have to do with losing weight? The answer is more interesting and more medically nuanced than much of the online conversation suggests.
First: what is a peptide?
Peptides are short chains of amino acids, the same basic building blocks used to make proteins. Your body naturally produces many peptides. Some act as signalling molecules, carrying instructions between cells and helping regulate biological processes including appetite, digestion, metabolism and hormone activity.
Scientists can also develop medications that mimic or modify the activity of naturally occurring peptide hormones.
That is where peptides have become particularly important in modern weight-loss medicine.
What do peptides have to do with appetite?
Your appetite is not controlled simply by willpower. The body uses a complex system of signals between the gut, brain, pancreas and other organs to influence hunger, fullness, blood sugar and energy balance.
One of those signals is GLP-1, or glucagon-like peptide-1.
Medications that activate the GLP-1 receptor can reduce appetite and calorie intake and improve glucose regulation. Tirzepatide acts on both GIP and GLP-1 receptors, targeting two metabolic signalling pathways rather than one.
For many patients, changing these biological signals can make weight loss feel very different from repeatedly trying to overpower hunger through restriction alone.
Are semaglutide and tirzepatide peptides?
They are peptide-based medications designed to act on specific metabolic pathways. Semaglutide acts primarily through the GLP-1 receptor, while tirzepatide acts through both GIP and GLP-1 receptors.
These therapies represent an important shift in obesity medicine because they address some of the biological mechanisms involved in appetite and weight regulation rather than relying exclusively on diet and exercise.
Why are these treatments getting so much attention?
Quite simply, the clinical results have been significant. Modern incretin-based medications have produced average weight reductions substantially beyond what was historically achieved with many older obesity medications. In a direct 72-week comparison in adults with obesity without diabetes, both semaglutide and tirzepatide produced substantial weight loss, with greater average reduction in the tirzepatide group.
That has changed the conversation around obesity treatment. For some patients, medical treatment can provide the early progress that makes broader lifestyle change easier to sustain.
But “peptide” does not automatically mean safe or effective
This distinction matters. The word peptide describes a very broad category. It is not a stamp of medical approval.
Some peptide-based treatments have extensive clinical evidence and regulatory approval for specific uses. Others remain investigational. Products promoted online may not have been evaluated to the same standards for safety, effectiveness, purity or manufacturing quality.
For example, the U.S. FDA has specifically warned about unapproved versions of GLP-1 medicines, noting that they do not undergo the agency’s review for safety, effectiveness and quality before being marketed.
That is one reason patients should be cautious about choosing a product simply because it is described online as a “weight-loss peptide.”
What about newer peptides?
Research in obesity and metabolic medicine continues to move quickly.
Scientists are studying therapies that target different combinations of metabolic pathways, with the aim of improving weight loss and other health outcomes.
Some are promising, but promising is not the same as proven, and investigational therapies should be described as investigational.
A responsible medical discussion should distinguish between treatments supported by established clinical evidence and newer therapies that are still being studied.
Why medical assessment matters
The question should not be “Which peptide should I take?” A better question is “What treatment, if any, is medically appropriate for me?”
Before recommending treatment, a physician needs to understand factors such as your weight history, medical conditions, medications, previous treatment, metabolic health and goals.
Treatment also needs to be monitored. Weight-loss medicines can have side effects and contraindications, and the appropriate medication and dose can differ substantially from one person to another.
Medication can create momentum. What you build around it matters.
Medical treatment can make weight loss more achievable for some people, but the objective should be larger than simply getting the number on the scale down.
The real goal is to lose the weight and make the change sustainable.
That means using the period of active weight loss to build practical habits around food, movement and everyday life, then having a strategy for maintaining progress afterwards.
At The Weight Clinic, that is the thinking behind LOSE. BUILD. SUSTAIN. Medical treatment can help create progress, progress can create momentum, and what you build around that momentum can help determine what happens next.
Start with an assessment, not an injection
If you are considering GLP-1 medications, peptide-based therapies or medical weight management generally, you do not need to arrive knowing which treatment you want.
That is what the medical assessment is for. You can also read our guide to semaglutide vs tirzepatide if you want to understand how two of the best-known treatments differ.
At The Weight Clinic, your first step is a consultation with Dr. Lorenzo Gordon, MD, MPhil, PhD, whose work spans diabetes, obesity, metabolic health, biochemistry, clinical research and medical education.
Physician consultation: J$10,000
Start with Dr. Gordon. Understand your options. Get a plan.
Sources: U.S. Food and Drug Administration guidance on unapproved GLP-1 drugs; Aronne et al., New England Journal of Medicine, SURMOUNT-5 (2025). Investigational therapies should not be treated as established treatment.